Oil markets are under pressure as the U.S. Strategic Petroleum Reserve sits below 300 million barrels and a historic supply disruption unsettles global trade routes. That kind of strain can ripple through inflation expectations, interest rates, and dividend plans. This article looks at three dividend growth stocks from our screener that are exposed to these headlines and explains why they may matter for investors who care about reliable and growing income streams.

The stocks covered below are just a sample of the income ideas that fit this dividend growth theme. The full screen surfaced 4 more companies with equally compelling stories that are not included in this article. If you want to go straight to the source, use the Dividend Growth Stocks screener to identify, filter, and analyze dividend growth stocks that best match your own income goals.

ResMed (RMD)

ResMed is a US medical technology company that makes sleep apnea and respiratory care devices, supported by cloud software that helps doctors and home care providers monitor and manage patients. Most of its revenue comes from Sleep and Breathing Health products at about US$5.0b, with Residential Care Software contributing around US$700 million, which gives it both equipment and subscription style income. The stock sits in large-cap territory with a market value of roughly US$30.6b.

ResMed stands out in a choppy, oil-sensitive market because its core demand is tied to sleep health and chronic respiratory care rather than energy prices. The company combines a sizeable hardware business with recurring digital platforms like AirView and Brightree, which can support margins even as growth guidance has recently turned more cautious. Analysts still see value in the stock, backed by a P/E that sits below many medical equipment peers and a higher estimated cash flow value. However, device issues such as the Astral corrective action and competitive pressure from alternatives like GLP-1 therapies are real risks. For dividend growth investors who want healthcare exposure and a large-cap profile, ResMed is a stock worth a closer look.

ResMed’s mix of hardware and recurring software revenue has investors asking whether the current P/E and cash flow profile leave a gap in the story. Review the DCF valuation analysis for ResMed to see what the market might be missing.

Build your own dividend growth shortlist

ResMed and the two other dividend growth stocks in this list all surfaced from a single Simply Wall St screen, but the real edge comes when you shape the filters yourself. Use our flexible Screener to mix metrics like valuation, balance sheet strength, risks, and dividends, or tap into our curated Investing Ideas for ready made starting points.

Port of Tauranga (NZSE:POT)

Port of Tauranga runs New Zealand’s largest port, handling container, bulk, and log cargo through its Tauranga, MetroPort, and Timaru terminals, and also earns income from property and logistics services linked to these assets. Most revenue comes from Port Operations at about NZ$431 million, with Property Services adding around NZ$49 million and Logistics Services roughly NZ$26 million. The stock sits firmly in large cap territory with a market value of about NZ$5.6b.

Income focused investors may find Port of Tauranga interesting because it owns essential infrastructure with high margins and has a record of growing earnings. This can help support dividends when energy markets are unsettled and inflation expectations are shifting. At the same time, the stock trades on a rich P/E and recent profit included a one off NZ$46.7 million gain, so future returns rely on the core port and logistics business continuing to justify that premium without the help of temporary boosts.

Port of Tauranga’s rich P/E and recent one off gain raise a simple question: Is the core port business really priced for what comes next or for what has already happened with the analysis report for Port of Tauranga?

Stryker (SYK)

Stryker is a large US medical technology company that supplies surgical equipment, joint replacement implants and neurotechnology products to hospitals and doctors in more than 60 countries. It generates about US$9.7b from Orthopaedics and roughly US$16.1b from MedSurg and Neurotechnology, giving it a broad mix of joint replacements, surgical tools, stroke care products and hospital equipment. The stock is firmly in mega cap territory with a market value of about US$130.0b.

Investors looking for dividend growth often turn to Stryker because it blends scale, medical procedure demand and a track record of steady cash generation, supported recently by 9% organic sales growth, margin expansion and a higher full year earnings outlook. The company is leaning into hospital digitization and robotic surgery platforms like Mako, which can deepen customer relationships and support pricing power. A recent 4.8% year on year dividend raise underlines its income credentials even as oil markets create volatility elsewhere. At the same time, high debt levels, regulatory delays and ongoing cyber and supply chain clean up mean this is not a risk free story. This is exactly why a closer look at Stryker’s balance between resilience and valuation could be worthwhile for long term income focused investors.

Stryker’s accelerating hospital tech push and 9% organic sales growth sit beside debt, regulatory and cyber clean up questions. Put the pieces together with the analysis report for Stryker

Seeking Alternatives While Curiosity Is High

Fresh ideas can move quickly when momentum builds and others are caught flat footed. Scan these under the radar stock lists before potential entry points change.

• Review the 52 high quality undervalued stocks to explore potential turnaround stories that may still be under the radar while pricing pressure keeps expectations in check.
• Consider major infrastructure spending themes by checking the 37 power grid technology and infrastructure stocks that focus on grid upgrades, transmission technology, and critical hardware.
• Look into robotics-related opportunities by scanning the curated 37 robotics and automation stocks that includes companies helping automate factories, warehouses, and services.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.